Conflict of interest statement: There are no conflicts of interest172. Breast J. 2018 Jul;24(4):459-461. doi: 10.1111/tbj.12932.Treatment of HER2-positive early breast cancer: How to best balance efficacy and toxicity?Azim HA(1), Lasheen S(1), Kassem L(1).Author information: (1)The Department of Clinical Oncology, School of Medicine, Cairo University,Cairo, Egypt.DOI: 10.1111/tbj.12932 PMID: 29998620 